Efficient retroviral gene transfer to the liver in vivo using nonpolypeptidic mitogens.
Recombinant retroviral vectors are attractive tools for achieving sustained expression of a therapeutic gene in the liver. However, cell division is required for efficient transduction with these vectors. Here we report that two widely used liver mitogens, triiodothyronin (T3) and cyproterone acetate (CPA), enable hepatocyte transduction with recombinant retroviral vectors delivered in vivo into the bloodstream. Treatment with T3 as well as CPA, alone or in combination, resulted in an increase in hepatocyte replication predominantly around the portal tract. The mitogenic activity made it possible to transduce hepatocytes in the same location. Moreover, when administered together, the two drugs synergized and the transduction level reached 5% of hepatocytes. This transduction level is compatible with clinical applications for a number of inherited liver diseases. Since these two compounds have a long history of safe clinical use, we propose that these liver mitogens may have potential for clinical application in liver-directed gene therapy.
Pichard
V
V
Laboratoire de Thérapie Génique, Hôtel-Dieu, Centre Hospitalier Universitaire de Nantes, Nantes cedex 01, 44035, France.
Aubert
D
D
Ferry
N
N
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017373:Cyproterone Acetate / Q000494:pharmacology*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D022781:Hepatocytes / Q000378:metabolism; D007150:Immunohistochemistry; D008099:Liver / Q000378:metabolism*; D008297:Male; D008934:Mitogens; D008938:Mitosis; D051381:Rats; D017208:Rats, Wistar; D012190:Retroviridae / Q000235:genetics*; D013997:Time Factors; D014161:Transduction, Genetic; D014284:Triiodothyronine / Q000494:pharmacology*; D001616:beta-Galactosidase / Q000378:metabolism
D000970:Antineoplastic Agents; D008934:Mitogens; D014284:Triiodothyronine; D017373:Cyproterone Acetate; D001616:beta-Galactosidase